Vor Biopharma (NASDAQ:VOR) Shares Down 7.2% - What's Next?

Key Points

• Vor Biopharma's stock declined by 7.2% to $28.22 from a previous close of $30.40, with trading volume decreasing significantly to 122,804 shares.
• Analysts have given mixed ratings for Vor Biopharma, with Zacks upgrading it to a "hold" and HC Wainwright to a "strong-buy", while Wall Street Zen issued a "strong sell" rating.
• The company reported a loss of ($2.18) EPS for the last quarter, missing analysts' expectations by ($1.61).

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) was down 7.2% during mid-day trading on Friday . The stock traded as low as $27.73 and last traded at $28.22. Approximately 122,804 shares changed hands during trading, a decline of 67% from the average daily volume of 377,393 shares. The stock had previously closed at $30.40.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on VOR shares. Wall Street Zen cut shares of Vor Biopharma to a "strong sell" rating in a research note on Saturday, June 28th. Zacks Research upgraded shares of Vor Biopharma from a "strong sell" rating to a "hold" rating in a report on Wednesday, September 10th. Finally, HC Wainwright upgraded shares of Vor Biopharma from a "hold" rating to a "strong-buy" rating in a report on Monday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Vor Biopharma has an average rating of "Buy".

Vor Biopharma Trading Up 2.5%

The stock has a market cap of $176.80 million, a PE ratio of -0.10 and a beta of 2.05. The business has a fifty day simple moving average of $39.97.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.